Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Trims Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. reduced its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 9.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 429,392 shares of the company's stock after selling 42,344 shares during the period. Janux Therapeutics makes up about 2.8% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s holdings, making the stock its 17th largest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.82% of Janux Therapeutics worth $22,990,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. RA Capital Management L.P. boosted its holdings in Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after purchasing an additional 1,200,000 shares during the period. FMR LLC raised its position in shares of Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after buying an additional 845,266 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after buying an additional 1,038,996 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its stake in Janux Therapeutics by 46.5% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after buying an additional 1,115,412 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its position in Janux Therapeutics by 47.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after buying an additional 986,750 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, April 21st. The shares were sold at an average price of $30.00, for a total value of $100,020.00. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at $2,464,170. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 10,001 shares of company stock valued at $313,964. 29.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Scotiabank decreased their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. Finally, Wedbush reiterated an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Price Performance

NASDAQ JANX traded up $0.01 on Friday, reaching $25.22. 1,181,341 shares of the company's stock traded hands, compared to its average volume of 874,124. The stock has a market cap of $1.49 billion, a PE ratio of -21.56 and a beta of 3.24. Janux Therapeutics, Inc. has a 12 month low of $22.48 and a 12 month high of $71.71. The stock has a 50-day simple moving average of $28.03 and a 200 day simple moving average of $39.59.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.